Q32 Bio Inc. Cash Flow Statement
QTTB|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Q32 Bio Inc. used $68M in operating cash flow and negative free cash flow of $68M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$47.7M | -$53.7M | -$5.0M | -$95.8M | -$128.7M | -$103.9M | -$55.6M | -$30.0M |
| Depreciation & Amortization | $487.0K | $499.0K | $1.3M | $8.4M | $8.0M | $6.3M | $1.3M | $684.0K |
| Operating Cash Flow | -$67.7M | -$18.7M | -$113.7M | -$109.8M | -$94.3M | -$91.4M | -$42.6M | $6.5M |
| Capital Expenditures | $75.0K | $5.0K | $1.3M | $2.4M | $3.7M | $21.8M | $24.9M | $2.0M |
| Free Cash Flow | -$67.8M | -$18.7M | -$114.9M | -$112.1M | -$98.1M | -$113.2M | -$67.5M | $4.5M |
| FCF Margin | - | 280.9% | -3583.1% | -330.1% | -3629.4% | -6794.2% | -1268.3% | 122.7% |